AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...
For the freshest news, join The Borneo Post's Telegram Channel and The Borneo Post on Newswav.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback